From Drug Store News:
The Food and Drug Administration on Friday announced its approval of Teva’s abbreviated new drug application the first generic of Gilead’s Truvada (emtricitabine and tenofovir disoproxil).
The drug is indicated both as a treatment for HIV-1 in combination with other antiretroviral drugs and for pre-exposure prophylaxis to prevent sexually acquired HIV infection in combination with safer sex practices.
What’s not clear at this point is whether Gilead will continue their medication assistance program, which provides PrEP for a large number of individuals who don’t have insurance, once this gets approved.
According to reports, Truvada ranks 17th in the top 20 meds in the U.S.
(h/t Randy Report reader Aaron)